747MO First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase II biomarker-directed platform study: Cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)

Isabelle Laure Ray-Coquard, Sandro Pignata, June‐Yong Lee, Robert L. Coleman, Janet E. Brown, JW Kim, Frédèric Selle, Domenica Lorusso, M.J. Bermejo-Pérez, P. Pautier, Charlie Gourley, Ali̇ Ayhan, Gary Richardson, D. Cibula, Lauren E. Yauch, Max Dieterich, Venkatesh Krishnan, O. Calas-Zeroug, Philipp Harter, David M. Gershenson